NEWS HIGHLIGHTS
Published Studies Related to Nystop (Nystatin Topical)
Clinical study on the dose-effect relationship of a nifuratel-nystatin combination in the treatment of vulvo-vaginal infections. [2003]
CONCLUSION: The results confirmed a linear relationship between nifuratel + nystatin dose and effect. The least effective dose was nifuratel 250 mg + nystatin 100,000 IU once daily for 5 days and the best dose in terms of risk/benefit ratio was nifuratel 500 mg + nystatin 200,000 IU once daily for 5 days.
Perianal candidosis--a comparative study with mupirocin and nystatin. [1999.08]
OBJECTIVE: To assess the efficacy and clinical outcome of 2% mupirocin in a polyethylene glycol base and nystatin cream as treatment regimens in diaper candidosis. DESIGN: A prospective randomized comparative study... CONCLUSIONS: Both agents eradicated Candida, the major difference being the marked response of the diaper dermatitis to mupirocin. Mupirocin should be applied topically 3-4 times daily or with each diaper change and is an excellent antifungal agent.
Evolution of saliva and serum components in patients with oral candidosis topically treated with Ketoconazole and Nystatin. [1998]
The present study involves the analysis of some saliva components (SC) and serum components in patients with oral candidosis topically treated with Ketoconazole 2% (K) or Nystatin 100,000 IU (N). Twenty-four male and female patients, age range 39-82 years, were included in the study... Patients with oral candidosis treated locally exhibit not only an improvement in clinical manifestations but also a return to control values of altered SC.
Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. [1997.06]
A total of 167 human immunodeficiency virus (HIV)-infected patients with oropharyngeal candidiasis were randomly assigned to receive 14 days of therapy with liquid suspension fluconazole (100 mg once daily) or liquid nystatin (500,000 U four times daily)... Fluconazole oral suspension as a systemic therapy was more effective than liquid nystatin as a topical therapy in the treatment of oral candidiasis in HIV-infected patients and provided a longer disease-free interval before relapse.
A comparative trial of clotrimazole troches and oral nystatin suspension in recipients of renal transplants. Use in prophylaxis of oropharyngeal candidiasis. [1987.11.13]
An open study designed to compare the effectiveness and safety of clotrimazole troches with nystatin oral suspension in the prevention of oropharyngeal candidiasis was conducted. This study was performed as the troche form of clotrimazole was easier to administer and less costly than nystatin oral suspension...
Clinical Trials Related to Nystop (Nystatin Topical)
A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis [Completed]
In resource constrained societies and where HIV is a problem, oral thrush causes significant
morbidity. In adults, ketoconazole is used and sometimes oral nystatin. Both drugs are
relatively expensive compared to GV solution and ketoconazole has significant side effects
especially in association with some of the treatments for HIV related problems.
In children, either GV solutions or nystatin are used, GV is a fraction of the cost of
nystatin.
GV at 1% solution discolours the mouth (blue) and in the older child and adult would mark
them out as having HIV infections. A much more dilute solution of GV has proved equally
effective in vitro and would not carry the same cosmetic problem.
In this study of children, the investigators have compared the 3 solutions, 1% GV, 0. 00165%
GV and nystatin oral drops - all masked so that they look the same - to see if GV is more
effective than nystatin, and to see if the weaker solution of GV is as effective as the
stronger solution.
A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection. [Completed]
To evaluate the clinical toxicity, safety, and maximum tolerated dose (MTD) of intravenous
nystatin in patients with HIV infection. To evaluate the potential anti-HIV activity and
clinical pharmacology of intravenous nystatin.
A Study of Nystatin in HIV-Infected Patients [Completed]
To evaluate the clinical toxicity, safety, and potential anti-HIV activity of intravenous
nystatin in patients with HIV infection who have completed protocol FDA 103C. To evaluate the
safety and potential antiviral activity of intravenous nystatin and oral didanosine (ddI)
administered in an alternating regimen in this patient population.
Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC [Completed]
To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the
prevention of oral candidiasis in patients with AIDS or AIDS related complex (ARC) (group III
or IV, CDC classification).
A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes [Completed]
To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the
prophylaxis of oral candidiasis in patients with AIDS or AIDS related syndromes (group III or
IV, CDC classification)
|
